Grape King Bio Ltd (TPE:1707)
90.50
-0.50 (-0.55%)
Sep 8, 2026, 1:30 PM CST
Grape King Bio Revenue
Grape King Bio had revenue of 2.41B TWD in the quarter ending June 30, 2026, a decrease of -6.05%. This brings the company's revenue in the last twelve months to 10.12B, down -6.93% year-over-year. In the year 2025, Grape King Bio had annual revenue of 10.25B, down -8.14%.
Revenue (ttm)
10.12B
Revenue Growth
-6.93%
P/S Ratio
1.33
Revenue / Employee
20.20M
Employees
501
Market Cap
13.48B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.25B | -908.40M | -8.14% |
| Dec 31, 2024 | 11.16B | 524.54M | 4.93% |
| Dec 31, 2023 | 10.64B | 244.23M | 2.35% |
| Dec 31, 2022 | 10.39B | 592.99M | 6.05% |
| Dec 31, 2021 | 9.80B | 630.05M | 6.87% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| YungShin Global Holding | 7.84B |
| Standard Chemical & Pharmaceutical | 7.08B |
| Synmosa Biopharma | 6.68B |
| TTY Biopharm Company | 6.65B |
| ScinoPharm Taiwan | 3.07B |
| Center Laboratories | 1.66B |
| Orient Pharma | 1.52B |
| SCI Pharmtech | 1.26B |